Exosomal miRNA (miR-25, miR-122, miR-195, miR-21, and miR-125b) modulation could also detect EGFR mutation and sensitivity to gefitinib in NSCLC patients, suggesting the potential of exosomes to select patients for target therapy [73]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.